Longboard Pharmaceuticals, Inc. EBIT to Interest coverage
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| EBIT to Interest coverage | 0.0x | 0.0x | (53.5x) | 0.0x |
Longboard Pharmaceuticals, Inc. (LBPH) EBIT to Interest coverage comparison analysis
General
LTM EBIT to Interest coverage
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
LBPH key stats
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.0) 0.0% | (0.0) 0.0% | (0.0) 0.0% |
| Operating Expenses | 14.4 | 27.8 | 44.8 | 56.8 |
| Research & Development Expenses (R&D) | 4.6 | 19.8 | 34.6 | 43.8 |
| Selling, General & Administrative Expenses (SG&A) | 9.8 | 8.1 | 10.2 | 13.0 |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
| Interest Income | 0.0 | 0.1 | 0.8 | 2.4 |
| Interest Expense | 0.0 | 0.0 | 0.8 | 0.0 |
| Pre-tax Income | (14.4) | (27.8) | (43.9) | (54.4) |
% effective tax rate | (0.0) 0.1% | (0.1) 0.2% | (0.9) 1.9% | 0.0 0.0% |
% margin | (14.4) 0.0% | (27.7) 0.0% | (43.1) 0.0% | (54.4) 0.0% |
| EPS | (0.82) | (1.62) | (2.51) | (2.39) |
| Diluted EPS | (0.82) | (1.62) | (2.51) | (2.39) |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Longboard Pharmaceuticals, Inc.'s EBIT to Interest coverage?
As of today, Microsoft Corp's last 12-month EBIT to Interest coverage is (172.8x), based on the financial report for Sep 30, 2024 (Q3’2024). The average annual EBIT to Interest coverage for Longboard Pharmaceuticals, Inc. have been (69.7x) over the past three years, and (52.3x) over the past five years.
2) Is Longboard Pharmaceuticals, Inc.'s EBIT to Interest coverage Good?
As of today, Longboard Pharmaceuticals, Inc.'s EBIT to Interest coverage is (172.8x), which is lower than industry median of (31.1x). It indicates that Longboard Pharmaceuticals, Inc.'s EBIT to Interest coverage is Bad.